[1] WALDMAN A D,FRITZ J M,LENARDO M J.A guide to cancer immunotherapy:from T cell basic science to clinical practice[J]. Nat Rev Immunol,2020,20(11):651-668. [2] ROSENBERG S A.Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know[J]. Nat Rev Clin Oncol,2011,8(10):577-585. [3] SOMMERMEYER D,HUDECEK M,KOSASIH P L,et al.Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo[J]. Leukemia,2016,30(2):492-500. [4] ZAM W,ASSAAD A.Chimeric antigen receptor T-cells (CARs) in cancer treatment[J].Curr Mol Pharmacol,2022,15(3):532-546. [5] CHOW V A,SHADMAN M,GOPAL A K.Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma[J]. Blood,2018,132(8):777-781. [6] CERRANO M,RUELLA M,PERALES M A,et al.The advent of CAR T-cell therapy for lymphoproliferative neoplasms:integrating research into clinical practice[J]. Front Immunol,2020,11:888. [7] PAPATHANASIOU M M,STAMATIS C,LAKELIN M,et al.Autologous CAR T-cell therapies supply chain:challenges and opportunities?[J]. Cancer Gene Ther,2020,27(10/11):799-809. [8] RIZVI N A,MAZIÈRES J,PLANCHARD D,et al. Activity and safety of nivolumab,an anti-PD-1 immune checkpoint inhibitor,for patients with advanced,refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2,single-arm trial[J]. Lancet Oncol,2015,16(3):257-265. [9] KURTULUS S,MADI A,ESCOBAR G,et al. Checkpoint blockade immunotherapy induces dynamic changes in PD-1-CD8+ tumor-infiltrating T cells[J]. Immunity,2019,50(1):181-194.e6. [10] COULIE P G,LEHMANN F,LETHÉ B,et al.A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma[J]. Proc Natl Acad Sci USA,1995,92(17):7976-7980. [11] CHEN F J,ZOU Z Y,DU J,et al.Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors[J]. J Clin Invest,2019,129(5):2056-2070. [12] ANAGNOSTOU V,SMITH K N,FORDE P M,et al.Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer[J]. Cancer Discov,2017,7(3):264-276. [13] DAVIS L,TARDUNO A,LU Y C.Neoantigen-reactive T cells:the driving force behind successful melanoma immunotherapy[J]. Cancers,2021,13(23):6061. [14] BLASS E,OTT P A.Advances in the development of personalized neoantigen-based therapeutic cancer vaccines[J]. Nat Rev Clin Oncol,2021,18(4):215-229. [15] CHEN Y,XUE S A,BEHBOUDI S,et al.Ex vivo PD-L1/PD-1 pathway blockade reverses dysfunction of circulating CEA-specific T cells in pancreatic cancer patients[J]. Clin Cancer Res,2017,23(20):6178-6189. [16] RIZVI N A,HELLMANN M D,SNYDER A,et al.Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science,2015,348(6230):124-128. [17] HUNDER N N,WALLEN H,CAO J H,et al.Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1[J]. N Engl J Med,2008,358(25):2698-2703. [18] SHARMA P,ALLISON J P.Immune checkpoint targeting in cancer therapy:toward combination strategies with curative potential[J]. Cell,2015,161(2):205-214. [19] DUAN M,GOSWAMI S,SHI J Y,et al.Activated and exhausted MAIT cells foster disease progression and indicate poor outcome in hepatocellular carcinoma[J]. Clin Cancer Res,2019,25(11):3304-3316. [20] MCLANE L M,ABDEL-HAKEEM M S,WHERRY E J. CD8 T cell exhaustion during chronic viral infection and cancer[J]. Annu Rev Immunol,2019,37:457-495. [21] DEPIL S,DUCHATEAU P,GRUPP S A,et al.‘Off-the-shelf’ allogeneic CAR T cells:development and challenges[J]. Nat Rev Drug Discov,2020,19(3):185-199. [22] PEREZ C,GRUBER I,ARBER C.Off-the-shelf allogeneic T cell therapies for cancer:opportunities and challenges using naturally occurring “universal” donor T cells[J]. Front Immunol,2020,11:583716. [23] DAVEY M S,WILLCOX C R,BAKER A T,et al.Recasting human Vδ1 lymphocytes in an adaptive role[J]. Trends Immunol,2018,39(6):446-459. [24] CARRENO B M,MAGRINI V,BECKER-HAPAK M,et al.Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells[J]. Science,2015,348(6236):803-808. [25] JENSEN K D C,SU X Q,SHIN S,et al.Thymic selection determines gammadelta T cell effector fate:antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon gamma[J]. Immunity,2008,29(1):90-100. [26] SIMONI Y,BECHT E,FEHLINGS M,et al.Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates[J]. Nature,2018,557(7706):575-579. [27] JHUNJHUNWALA S,HAMMER C,DELAMARRE L.Antigen presentation in cancer:insights into tumour immunogenicity and immune evasion[J]. Nat Rev Cancer,2021,21(5):298-312. |